101.47

1.12% -1.15

After Hours: 101.48 0.01 +0.01%

Nuvalent Inc (NUVL)

Overview News Price History Option Chain Financials Why NUVL Down? Discussions Forecast

Nuvalent Inc stock is traded at $101.47, with a volume of 612.50K. It is down -1.12% in the last 24 hours and down -3.76% over the past month. Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Previous Close:

$102.62

Open:

$103.68

24h Volume:

612.50K

Relative Volume:

1.10

Market Cap:

$8.01B

Revenue:

Net Income/Loss:

$-425.38M

P/E Ratio:

-17.34

EPS:

-5.8504

Net Cash Flow:

$-275.21M

1W Performance:

-0.46%

1M Performance:

-3.76%

6M Performance:

+10.19%

1Y Performance:

+34.52%

1-Day Range:

$100.03

$104.42

1-Week Range:

$97.77

$104.42

52-Week Range:

$63.55

$113.02

Nuvalent Inc Stock (NUVL) Company Profile

Name

Nuvalent Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

508-446-2272

Address

ONE BROADWAY, 14TH FLOOR, CAMBRIDGE

Employee

228

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

NUVL's Discussions on Twitter

Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVL Nuvalent Inc	101.47	8.10B	0	-425.38M	-275.21M	-5.8504
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Nuvalent Inc Stock (NUVL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-30-26	Initiated	Wells Fargo	Overweight
Nov-24-25	Initiated	Truist	Buy
Nov-12-25	Initiated	Canaccord Genuity	Buy
Oct-16-25	Resumed	Stifel	Buy
Oct-15-25	Initiated	Cantor Fitzgerald	Overweight
Sep-04-25	Resumed	Guggenheim	Buy
Sep-03-25	Initiated	Raymond James	Outperform
Aug-19-25	Initiated	Piper Sandler	Overweight
Mar-14-25	Upgrade	UBS	Neutral → Buy
Dec-30-24	Initiated	H.C. Wainwright	Buy
Oct-24-24	Initiated	UBS	Neutral
Aug-29-24	Initiated	Barclays	Overweight
Apr-17-24	Initiated	Jefferies	Buy
Apr-01-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-28-24	Resumed	Guggenheim	Buy
Feb-23-24	Initiated	Robert W. Baird	Outperform
Sep-27-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	SVB Securities	Market Perform
Jul-24-23	Initiated	Guggenheim	Buy
Jan-18-23	Initiated	Wedbush	Outperform
Jun-24-22	Initiated	BMO Capital Markets	Outperform

View All

Nuvalent Inc Stock (NUVL) Latest News

May 05, 2026

Nuvalent CFO Balcom sells $1.13m in company stock - Investing.com

May 05, 2026

Nuvalent (NUVL) CFO sells 11,430 shares, exercises options under plan - Stock Titan

May 05, 2026

May 01, 2026

Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock - MarketBeat

May 01, 2026

Nuvalent Insider Sold Shares Worth $547,524, According to a Recent SEC Filing - marketscreener.com

May 01, 2026

Nuvalent Insider Sold Shares Worth $545,691, According to a Recent SEC Filing - marketscreener.com

May 01, 2026

Nuvalent (NUVL) CLO sells shares, exercises options in 10b5-1 plan - Stock Titan

May 01, 2026

Nuvalent (NUVL) CDO nets 5,500-share sale after option exercise - Stock Titan

May 01, 2026

Nuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLC - Yahoo Finance

May 01, 2026

Apr 30, 2026

NUVL (NASDAQ) Form 144: Affiliate to sell 16,500 shares via option exercise - Stock Titan

Apr 30, 2026

Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal (NASDAQ:NUVL) - Seeking Alpha

Apr 30, 2026

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform - BioSpace

Apr 30, 2026

Guardant Health partners with Nuvalent on diagnostic tests By Investing.com - Investing.com South Africa

Apr 30, 2026

Guardant Health partners with Nuvalent on diagnostic tests - Investing.com

Apr 30, 2026

Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent - Bitget

Apr 30, 2026

CCORF Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $126 - Moomoo

Apr 30, 2026

Pictet Asset Management Holding SA Has $35.78 Million Holdings in Nuvalent, Inc. $NUVL - MarketBeat

Apr 30, 2026

Nuvalent (NUVL) Projected to Post Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 29, 2026

Universal Beteiligungs und Servicegesellschaft mbH Has $4.70 Million Position in Nuvalent, Inc. $NUVL - MarketBeat

Apr 29, 2026

Apr 28, 2026

[ARS] Nuvalent, Inc. SEC Filing - Stock Titan

Apr 28, 2026

[DEF 14A] Nuvalent, Inc. Definitive Proxy Statement - Stock Titan

Apr 28, 2026

Apr 27, 2026

Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN

Apr 27, 2026